Physician profile
Mark E Skees
NPI 1861571499
$13,926.76
in general payments reported to CMS, 2019-2025
69 companies · $2,270 in 2025
The $2,270 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,733 · 2020: $1,529 · 2021: $2,285 · 2022: $2,156 · 2023: $1,813 · 2024: $2,141 · 2025: $2,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,124 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,124.11 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,409.08 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals Lp | $1,874.58 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,244.67 | 2019-2025 | |
| Novo Nordisk INC | $1,066.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $675.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $656.23 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $526.17 | 2019-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $468.62 | 2019-2021 | |
| Amgen INC. | $417.67 | 2019-2024 | Otezla, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.35 | 2019-2025 | Jardiance, Ofev |
| Astellas Pharma US INC | $346.05 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $287.62 | 2019-2024 | Dificid, Gardasil, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $245.56 | 2019-2024 | Trintellix |
| Allergan, INC. | $236.45 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $200.18 | 2022 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Skees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.